Corrigendum to: PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice (Journal of Cellular Biochemistry, (2010), 111, 1, (218-228), 10.1002/jcb.22691);PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice

Journal of Cellular Biochemistry

Volumn 111, Issue 1, 2010, Pages 218-228

  Zheng, Tongsen ^a   Meng, Xianzhi ^a   Wang, JiaBei ^a   Chen, Xi ^a   Yin, Dalong ^a   Liang, Yingjian ^a   Song, Xuan ^a   Pan, Shangha ^a   Jiang, Hongchi ^a   Liu, Lianxin ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Akt; FTY720; Gastric cancer; p53; PTEN

Indexed keywords

CISPLATIN; FINGOLIMOD; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STOMACH CANCER; UPREGULATION;

MUS MUSCULUS;

EID: 77956791246     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.30268     Document Type: Erratum

References (41)

1. Ajani JA. 1998. Chemotherapy for gastric carcinoma: New and old options. Oncology 12:44-47. (Pubitemid 28536408)
2. Bossy-Wetzel E, Green DR. 1999. Caspases induce cytochrome c release from mitochondria by activating cytosolic factors. J Biol Chem 274:17484-17490. (Pubitemid 29283256)
3. Brinkmann V, Pinschewer DD, Feng L, Chen S. 2001. FTY720: Altered lymphocyte traffic results in allograft protection. Transplantation 72:764-769.
4. Bykov VJ, Wiman KG. 2003. Novel cancer therapy by reactivation of the p53 apoptosis pathway. Ann Med 35:458-465.
5. Chua CW, Lee DT, Ling MT, Zhou C, Man K, Ho J, Chan FL, Wang X, Wong YC. 2005. FTY720, a fungus metabolite, inhibits in vivo growth of androgen independent prostate cancer. Int J Cancer 117:1039-1048.
6. Chua CW, Chiu YT, Yuen HF, Chan KW, Man K, Wang X, Ling MT, Wong YC. 2009. Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: Validating Runx2 as a potential antimetastatic drug screening platform. Clin Cancer Res 15(13):4322-4335.
7. Chung TW, Lee YC, Ko JH, Kim CH. 2003. Hepatitis B virus X protein modulates the expression of PTEN by inhibiting the function of p53, a transcriptional activator in liver cells. Cancer Res 63:3453-3458.
8. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ. 2006. MAGIC trial participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20.
9. Dvory-Sobol H, Sagiv E, Liberman E, Kazanov D, Arber N. 2007. Suppression of gastric cancer cell growth by targeting the beta-catenin/T-cell factor pathway. Cancer 109(2):188-197. (Pubitemid 46106233)
10. Fan D, Zhang X, Chen X, Mou Z, Hu J, Zhou S, Ding J, Wu K. 2005. Bird's-eye view on gastric cancer research of the past 25 years. J Gastroenterol Hepatol 20:360-365.
11. Fujita T, Inoue K, Yamamoto S, Ikumoto T, Sasaki S, Toyama R, Chiba K, Hoshino Y, Okumoto T. 1994. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot 47:208-215.
12. Graler MH, Goetzl EJ. 2004. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 18:551-553.
13. Greenlee RT, Murray T, Bolden S, Wingo PA. 2000. Cancer statistics. CA Cancer J Clin 50:7-33.
14. Han Z, Hong L, Han Y, Wu K, Han S, Shen H, Li C, Yao L, Qiao T, Fan D. 2007. Phospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gp, Bcl-2 and Bax. J Exp Clin Cancer Res 26:261-268. (Pubitemid 47025290)
15. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816. (Pubitemid 23346377)
16. Ho JW, Man K, Sun CK, Lee TK, Poon RT, Fan ST. 2005. Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. Mol Cancer Ther 4:1430-1438.
17. Hou P, Ji M, Xing M. 2008. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer 113(9):2440-2447.
18. Hung JH, Lu YS, Wang YC, Ma YH, Wang DS, Kulp SK, Muthusamy N, Byrd JC, Cheng AL, Chen CS. 2008. FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling. Cancer Res 68(4):1204-1212.
19. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW, FTY720 D2201 Study Group. 2006. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355:1124-1140.
20. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E. 1997. New functional activities for the p21 family of CDK inhibitors. Genes Dev 11:847-862.
21. Lee TK, Man K, Ho JW, Sun CK, Ng KT, Wang XH, Wong YC, Ng IO, Xu R, Fan ST. 2004. FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation. Carcinogenesis 25:2397-2405.
22. Li XK, Tamura A, Fujino M, Guo L, Kakefuda T, Funeshima N, Enosawa S, Amari M, Naoe S, Amemiya H, Suzuki S. 2001. Induction of lymphocyte apoptosis in rat liver allograft with ongoing rejection by FTY720. Clin Exp Immunol 123(2):331-339.
23. Liu SQ, Yu JP, Yu HG, Lv P, Chen HL. 2006. Activation of Akt and ERK signaling pathways induced by etoposide confer chemoresistance in gastric cancer cells. Dig Liver Dis 38:310-318.
24. Liu Q, Zhao X, Frissora F, Ma Y, Santhanam R, Jarjoura D, Lehman A, Perrotti D, Chen CS, Dalton JT, Muthusamy N, Byrd JC. 2008. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 111(1):275-284.
25. Mayo LD, Donner DB. 2001. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of MDM2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 98:11598-11603.
26. Mayo LD, Donner DB. 2002. The PTEN, MDM2, p53 tumor suppressor- oncoprotein network. Trends Biochem Sci 27(9):462-467. (Pubitemid 35246255)
27. Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB. 2002. PTEN protects p53 from MDM2 and sensitizes cancer cells to chemotherapy. J Biol Chem 277:5484-5489.
28. Mezhir JJ, Tang LH, Coit DG. 2010. Neoadjuvant therapy of locally advanced gastric cancer. J Surg Oncol 101(4):305-314.
29. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, Roy DC, Caligiuri MA, Bloomfield CD, Byrd JC, Perrotti D. 2007. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 117(9):2408-2421.
30. O'Connor P, Comi G, Montalban X, Antel J, Radue EW, de Vera A, Pohlmann H, Kappos L, FTY720 D2201Study Group. 2009. Oral fingolimod (FTY720) in multiple sclerosis: Two-year results of a phase II extension study. Neurology 72(1):73-79.
31. Oki E, Baba H, Tokunaga E, Nakamura T, Ueda N, Futatsugi M, Mashino K, Yamamoto M, Ikebe M, Kakeji Y, Maehara Y. 2005. Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer 117:376-380.
32. Parekh DB, Katso RM, Leslie NR, Downes CP, Procyk KJ, Waterfield MD, Parker PJ. 2000. Beta1-integrin and PTEN control the phosphorylation of protein kinase C. Biochem J 352(Pt 2):425-433. (Pubitemid 32011436)
33. Permpongkosol S, Wang JD, Takahara S, Matsumiya K, Nonomura N, Nishimura K, Tsujimura A, Kongkanand A, Okuyama A. 2002. Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: Modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis. Int J Cancer 98:167-172.
34. Rivera F, Vega-Villegas ME, Lopez-Brea MF. 2007. Chemotherapy of advanced gastric cancer. Cancer Treat Rev 33:315-324.
35. Schmid G, Guba M, Ischenko I, Papyan A, Joka M, Schrepfer S, Bruns CJ, Jauch KW, Heeschen C, Graeb C. 2007. The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1. J Cell Biochem 101(1):259-270.
36. Shen Y, Cai M, Xia W, Liu J, Zhang Q, Xie H, Wang C, Wang X, Zheng S. 2007. FTY720, a synthetic compound from Isaria sinclairii, inhibits proliferation and induces apoptosis in pancreatic cancer cells. Cancer Lett 254:288-297.
37. Tedesco-Silva H, Mourad G, Kahan BD, Boira JG, Weimar W, Mulgaonkar S, Nashan B, Madsen S, Charpentier B, Pellet P, Vanrenterghem Y. 2004. FTY720, a novel immunomodulator: Efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 77:1826-1833.
38. Wang TH, Wang HS, Soong YK. 2000. Paclitaxel-induced cell death: Where the cell cycle and apoptosis come together. Cancer 88(11):2619-2628.
39. Yasui H, Hideshima T, Raje N, Roccaro AM, Shiraishi N, Kumar S, Hamasaki M, Ishitsuka K, Tai YT, Podar K, Catley L, Mitsiades CS, Richardson PG, Albert R, Brinkmann V, Chauhan D, Anderson KC. 2005. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res 65:7478-7484.
40. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. 2001. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 3:973-982. (Pubitemid 34428742)
41. Zhou C, Ling MT, Kin-Wah Lee T, Man K, Wang X, Wong YC. 2006. FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase. Cancer Lett 233: 36-47.